Skip to content
DraconiticResearch
Search Sources API
197,768 studies31 sourcesUpdated 5 min ago
Peer-reviewedCC BYFrontiers in oncology

CD163-positive macrophage enrichment is associated with mismatch repair deficiency and adverse pathologic features in early-stage endometrioid endometrial carcinoma: a retrospective cohort study

  1. 1Department of Pathology, Ganzhou Maternal and Child Health Hospital , ,
  2. 2Department of Obstetrics and Gynecology, Ganzhou Maternal and Child Health Hospital , ,

Abstract

Background: Mismatch repair deficiency defines an immunologically distinct subgroup of endometrioid endometrial carcinoma, but its relationship with CD163-positive macrophage infiltration in early-stage disease remains incompletely characterized. We evaluated the association between MMR status and quantitative CD163-positive TAM infiltration, together with secondary clinicopathologic and exploratory DFS analyses.

Methods: This single-center retrospective cohort included patients with surgically treated FIGO 2009 stage I–II endometrioid endometrial carcinoma and available formalin-fixed paraffin-embedded tumor tissue. Immunohistochemistry for MLH1, PMS2, MSH2, MSH6, and CD163 defined MMR status and quantified macrophage density. CD163-positive TAM density was analyzed quantitatively as the principal measure, with a cohort-median low/high categorization retained for secondary phenotypic analyses. Median regression evaluated the association between MMR status and continuous CD163-positive TAM density, whereas logistic regression was used for the secondary binary TAM analysis and the composite adverse pathologic endpoint. Exploratory DFS analyses included single-marker and combined Cox models, formal MMR-by-TAM interaction testing, and comparison of models with and without continuous CD163-positive TAM density.

Results: Among 254 patients assessed, 236 were included. MMR protein expression was retained in 172 tumors (72.9%), whereas 64 (27.1%) were classified as dMMR. CD163-positive TAM density was higher in dMMR than pMMR tumors (median, 76 vs 47 cells/HPF; P<0.001), and high TAM infiltration was more frequent in dMMR tumors (44/64, 68.8% vs 71/172, 41.3%; P<0.001). After adjustment for age, FIGO stage, tumor grade, tumor size, and deep myometrial invasion, dMMR remained associated with high macrophage infiltration (adjusted OR, 2.27; 95% CI, 1.19–4.18; P = 0.008). High macrophage infiltration was associated with grade 3 histology, deep myometrial invasion, LVSI, and the composite adverse pathologic feature; the association with the composite endpoint persisted after adjustment (adjusted OR, 1.78; 95% CI, 1.01–3.14; P = 0.047). During follow-up, 26 DFS events occurred. In exploratory Cox analyses, dMMR was associated with DFS (adjusted HR, 2.76; 95% CI, 1.25–6.10; P = 0.012), whereas continuous CD163-positive TAM density was not (adjusted HR per 10 cells/HPF, 1.04; 95% CI, 0.97–1.12; P = 0.281), and addition of CD163-positive TAM density did not significantly improve model fit beyond MMR status (likelihood-ratio P = 0.279). The dMMR/high-TAM phenotype retained an exploratory association with DFS in the conventional model (adjusted HR, 2.21; 95% CI, 1.02–4.81; P = 0.044), but the association was attenuated after additional adjustment for adjuvant therapy (HR, 2.04; 95% CI, 0.93–4.52; P = 0.075).

Conclusions: IHC-defined dMMR was associated with increased CD163-positive macrophage infiltration, and higher TAM infiltration was associated with adverse pathologic features. DFS findings were exploratory and did not establish incremental prognostic value of CD163-positive TAM infiltration beyond MMR status; larger externally validated cohorts are required to assess prognostic relevance.

Related

  1. Association of VCP/p97 Expression with Clinicopathological Features and Overall Survival in Endometrioid Endometrial Carcinoma
    Akgül Arıcı, Elif Akçay, Kübra Arslan +2
    BiomedicinesPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Case Report: Primary endometrioid adenocarcinoma of the cervix and secondary cervical involvement by endometrial carcinoma: diagnostic pitfalls and an integrated approach based on two cases
    Lina Geng, Tianci Fan, Guanwen Gao +2
    Frontiers in reproductive healthPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Recurrence patterns and adjuvant therapy in endometrioid early-stage endometrial cancer with a p53-abnormal pattern
    S. h. Lee, P. D. Karimah, K. KIM +6
    medRxivPreprintCC BY-NCFull textObstetrics, gynaecology & paediatricsmedRxiv
  4. Metformin as an Adjunct to Fertility-Sparing Treatment in Atypical Endometrial Hyperplasia and Early-Stage Endometrioid Endometrial Cancer: Narrative Review.
    Angel Yordanov, Eva Tsoneva, Stoyan Kostov +2
    CancersPeer-reviewedCC BYFull textObstetrics, gynaecology & paediatricsEurope PMC
  5. An interpretable multimodal morphomolecular model refines progression-risk stratification in early-stage endometrioid endometrial carcinoma
    Jinxin Li, Qiong Tang, Jinyang Chen +5
    Frontiers in cell and developmental biologyPeer-reviewedCC BYFull textObstetrics, gynaecology & paediatricsEurope PMCPMCEurope PMC
BibTeX
@article{chen2026cd163positive,
  title = {{CD163-positive macrophage enrichment is associated with mismatch repair deficiency and adverse pathologic features in early-stage endometrioid endometrial carcinoma: a retrospective cohort study}},
  author = {Donglian Chen and Xiaojuan Huang and Yu Zhang and Linhong Liao and Qianqian Ye and Yu Guo},
  journal = {Frontiers in oncology},
  year = {2026},
  month = oct,
  doi = {10.3389/fonc.2026.1954599},
  url = {https://europepmc.org/article/PMC/PMC13671934},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - CD163-positive macrophage enrichment is associated with mismatch repair deficiency and adverse pathologic features in early-stage endometrioid endometrial carcinoma: a retrospective cohort study
AU  - Donglian Chen
AU  - Xiaojuan Huang
AU  - Yu Zhang
AU  - Linhong Liao
AU  - Qianqian Ye
AU  - Yu Guo
PY  - 2026
DA  - 2026/10/02
JO  - Frontiers in oncology
DO  - 10.3389/fonc.2026.1954599
UR  - https://europepmc.org/article/PMC/PMC13671934
AB  - Background: Mismatch repair deficiency defines an immunologically distinct subgroup of endometrioid endometrial carcinoma, but its relationship with CD163-positive macrophage infiltration in early-stage disease remains incompletely characterized. We evaluated the association between MMR status and quantitative CD163-positive TAM infiltration, together with secondary clinicopathologic and exploratory DFS analyses.  Methods: This single-center retrospective cohort included patients with surgically treated FIGO 2009 stage I–II endometrioid endometrial carcinoma and available formalin-fixed paraffin-embedded tumor tissue. Immunohistochemistry for MLH1, PMS2, MSH2, MSH6, and CD163 defined MMR status and quantified macrophage density. CD163-positive TAM density was analyzed quantitatively as the principal measure, with a cohort-median low/high categorization retained for secondary phenotypic analyses. Median regression evaluated the association between MMR status and continuous CD163-positive TAM density, whereas logistic regression was used for the secondary binary TAM analysis and the composite adverse pathologic endpoint. Exploratory DFS analyses included single-marker and combined Cox models, formal MMR-by-TAM interaction testing, and comparison of models with and without continuous CD163-positive TAM density.  Results: Among 254 patients assessed, 236 were included. MMR protein expression was retained in 172 tumors (72.9%), whereas 64 (27.1%) were classified as dMMR. CD163-positive TAM density was higher in dMMR than pMMR tumors (median, 76 vs 47 cells/HPF; P<0.001), and high TAM infiltration was more frequent in dMMR tumors (44/64, 68.8% vs 71/172, 41.3%; P<0.001). After adjustment for age, FIGO stage, tumor grade, tumor size, and deep myometrial invasion, dMMR remained associated with high macrophage infiltration (adjusted OR, 2.27; 95% CI, 1.19–4.18; P = 0.008). High macrophage infiltration was associated with grade 3 histology, deep myometrial invasion, LVSI, and the composite adverse pathologic feature; the association with the composite endpoint persisted after adjustment (adjusted OR, 1.78; 95% CI, 1.01–3.14; P = 0.047). During follow-up, 26 DFS events occurred. In exploratory Cox analyses, dMMR was associated with DFS (adjusted HR, 2.76; 95% CI, 1.25–6.10; P = 0.012), whereas continuous CD163-positive TAM density was not (adjusted HR per 10 cells/HPF, 1.04; 95% CI, 0.97–1.12; P = 0.281), and addition of CD163-positive TAM density did not significantly improve model fit beyond MMR status (likelihood-ratio P = 0.279). The dMMR/high-TAM phenotype retained an exploratory association with DFS in the conventional model (adjusted HR, 2.21; 95% CI, 1.02–4.81; P = 0.044), but the association was attenuated after additional adjustment for adjuvant therapy (HR, 2.04; 95% CI, 0.93–4.52; P = 0.075).  Conclusions: IHC-defined dMMR was associated with increased CD163-positive macrophage infiltration, and higher TAM infiltration was associated with adverse pathologic features. DFS findings were exploratory and did not establish incremental prognostic value of CD163-positive TAM infiltration beyond MMR status; larger externally validated cohorts are required to assess prognostic relevance.
SN  - 2234-943X
ER  -